Last reviewed · How we verify

Sufentanil injection

Eye & ENT Hospital of Fudan University · FDA-approved active Small molecule

Sufentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce analgesia and sedation.

Sufentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce analgesia and sedation. Used for Perioperative analgesia and sedation during anesthesia, Acute postoperative pain management.

At a glance

Generic nameSufentanil injection
Also known assufentanil, Sufenta®, Johnson&Johnson, USA, 108/26, 15.08.2000, adenotonsillectomy
SponsorEye & ENT Hospital of Fudan University
Drug classOpioid agonist
TargetMu (μ) opioid receptor
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Sufentanil activates mu opioid receptors, which are G-protein coupled receptors distributed throughout the brain and spinal cord. This activation inhibits the transmission of pain signals and produces profound analgesia, sedation, and respiratory depression. It is approximately 5-10 times more potent than fentanyl and is used primarily for perioperative anesthesia and analgesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results